How to Sell GLP-1 Products Online Legally

GLP-1 is the largest opportunity in this category and the one with the least tolerance for shortcuts. The compliant structure is not complicated, it is just non-negotiable: a licensed prescriber, a real patient evaluation, a patient-specific prescription, and a licensed pharmacy that fills it. Everything you build online sits on top of that.

If you are looking for a way to sell GLP-1 medication without a prescriber, there is not one, and every workaround you have seen advertised eventually produces a state board action, a merchant account termination, or both. What follows is how to do it correctly and still build a business that scales.

the legal structure

1. 1.A clinical entity, typically owned by licensed providers where corporate practice of medicine rules require it, employing or contracting the prescribers.
2. 2.A management services organization that owns the brand, the website, the marketing, and the technology, contracting with the clinical entity under a management services agreement at fair market value.
3. 3.Prescriber licensure in every state you intend to treat patients in, plus compliance with each state's telehealth requirements for establishing a patient relationship.
4. 4.A pharmacy partner: a 503A compounding pharmacy filling patient-specific prescriptions, or a 503B outsourcing facility if you are working with office stock where permitted.
5. 5.A compliant intake that captures medical history, contraindications, and consent, and routes to a provider for actual review rather than rubber stamping.
6. 6.Documented clinical protocols, follow-up cadence, and adverse event reporting.

That last one gets skipped constantly and it is the one a regulator asks about first.

compounded versus brand: know where you stand

The compounding landscape for GLP-1 has moved repeatedly. When a drug is in shortage, compounding rules are one thing; when it comes off the shortage list, they change, and 503A pharmacies face significant restrictions on producing what are effectively copies of commercially available products. Personalization arguments have limits and regulators have pushed back on them.

Practically, this means two things for your business. First, do not build a business model that depends on a specific compounding allowance staying in place, because it may not. Second, choose a pharmacy partner who is transparent about their legal basis for what they are producing, and get your attorney to review it. If your pharmacy cannot explain their position clearly, that is your answer.

Many operators run a mixed model: a compounded program where legally supportable, plus a pathway to branded product through a prescriber for patients who want it and can access it. Diversification protects the business against a single regulatory shift.

the economics

GLP-1 programs are unusually good businesses when structured well, because the product is inherently recurring and the patient is highly motivated.

• —Program pricing typically runs $199 to $549 per month depending on market, product, and level of clinical support included.
• —Clinic or brand cost per month of compounded product typically runs $150 to $260, though this moves with supply conditions.
• —Gross margin per month lands between 45 and 65 percent, recurring.
• —Average program duration runs 4 to 8 months, so lifetime value commonly sits between $900 and $3,000.
• —That LTV supports a customer acquisition cost of $150 to $400, which is what makes paid acquisition viable at scale in this category.

Two costs people forget: provider time per patient per month, which is real and should be modeled at $15 to $40, and the support burden, which is heavier than any other category we work in. Budget for staffed support or your reviews and chargebacks will both suffer.

advertising GLP-1 without getting your account shut down

Meta treats this as a sensitive category and enforces hard. The rules that matter:

• —No personal attributes. You cannot address the viewer as though you know their weight, health status, or body. No versions of 'struggling with your weight' framed at the viewer.
• —No before-and-after imagery, no scale imagery, no body transformation visuals. This is the fastest rejection in the category.
• —No specific outcome claims. No pound counts, no timelines, no guaranteed results.
• —No implied diagnosis and no medical claims your prescriber relationship does not support.
• —Your landing page has to match your ad. Mismatch triggers manual review and manual review is where accounts get restricted.

What works inside those rules: provider credibility, program structure, support quality, transparency about how the process works, and honest framing of who the program is not for. On WayyLess we put $4.3M into Meta and got $19.1M out at a 4.45 blended ROAS running compliant creative. The constraint is real and it is survivable.

payments and fulfillment specifics

Telehealth and prescription programs are high-risk merchant categories. Mainstream gateways will decline or terminate. You need a high-risk acquirer that has underwritten the exact model, including recurring billing, and you should expect a rolling reserve. Recurring billing raises the chargeback stakes, so your cancellation flow needs to be frictionless and your billing descriptor unmistakable. Most chargebacks in this category are I-did-not-recognize-this-charge, not disputes about the product.

On fulfillment: compounded GLP-1 typically ships from the pharmacy directly to the patient with cold chain packaging and transit time limits. Your job is to make sure the patient knows when it arrives, how to store it, and who to call. Failed first deliveries are the leading cause of first-month churn.

retention: the part that determines whether this works

1. 1.Day 0: onboarding sequence covering what to expect, storage and handling, and how to reach support.
2. 2.Day 3: delivery confirmation and a first check-in. Catch problems before they become chargebacks.
3. 3.Week 2: side effect and tolerance check-in from clinical staff. This single touchpoint moves month-two retention more than anything else.
4. 4.Week 4: refill confirmation and provider follow-up, scheduled automatically.
5. 5.Month 3: program review, dose or plan adjustment where clinically appropriate, and a prepay offer.
6. 6.Off-program: a maintenance pathway so patients who complete do not simply disappear.

in glp-1, acquisition is a solved problem and retention is the whole business. a two-minute clinical check-in in week two is worth more than a point of roas.

This is not legal or medical advice. GLP-1 regulation, compounding permissions, and state telehealth rules change frequently. Retain a healthcare regulatory attorney, confirm your pharmacy partner's legal basis in writing, and revisit both regularly.